Metabolic Syndrome Market Analysis

Treatment (Pharmaceuticals, Surgery, Lifestyle Management)

The pharmaceuticals segment is expected to capture metabolic syndrome market share of over 38% by 2037. The demand for strong medicines that can address major factors like obesity, diabetes, or high cholesterol is expected to boost this growth. In March 2023, Regeneron Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration had extended the indication of the usage of Evkeeza (evinacumab-dgnb) in addition to other lipid-lowering therapies in pediatric patients 5–11 years of age with homozygous familial hypercholesterolemia. This underlines new medicines that aim particularly at managing metabolic risk factors.

Type of Metabolic Syndrome (Type 1 Metabolic Syndrome, Type 2 Metabolic Syndrome, Type 3 Metabolic Syndrome)

In metabolic syndrome market, Type 2 metabolic syndrome segment is set to capture revenue share of over 54.5% by 2037 due to the coverage of obesity, high cholesterol, and insulin resistance. The wide prevalence of type 2 diabetes worldwide accelerates demand for its comprehensive management. For example, Eli Lilly announced in April 2023 that data from the SURMOUNT-2 study were presented in patients with type 2 diabetes and obesity who saw a weight reduction. The presented data underlined the demand for targeted solutions in the management of type 2 metabolic syndrome.

Our in-depth analysis of the metabolic syndrome market includes the following segments